AbbVie has today announced that it is set to acquire Gilgamesh Pharmaceuticals’ lead candidate, GM-2505 (aka bretisilocin, a serotonergic psychedelic), which is under development for major depressive disorder (MDD).
Under the terms of the deal, the large pharmaceutical company will acquire the bretisilocin program for up to $1.2 billion, including an upfront payment and development milestones, though the split is not publicly known.
Gilgamesh will also spin out a new entity, ‘Gilgamesh Pharma Inc.’, which will retain its employees and other programs, like its oral NMDAR antagonist (GM-1020), ‘safer’ ibogaine analog (GM-3009), its M1/M4 agonist program, and other collaborative work with AbbVie. The option-to-license agreement with AbbVie will also be transferred to the spinout.
Here, we take a closer look at the acquisition, what it might tell us about big pharma’s interest in the field, and what it might mean for the broader crop of psychedelic drug developers…
Sign-in or join Pα+ to continue reading this article…
Join Pα+ Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue
